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Nitric oxide release in the peripheral blood during hemodialysis. These
studies evaluated the nitric oxide (NO) release in peripheral blood during
a four-hour hemodialysis (HD) with single-used cuprophane (CU), poly-
sulfone (PS) and polyacrylonitrile (PAN) membranes in 10 chronic uremic
patients. Continuous monitoring of blood NO concentrations was per-
formed with a sterile NO sensor probe inserted vertically into the arterial
blood line between the arteriovenous fistula and dialyzer. In the initial
period of HD two peaks of blood NO concentrations were observed: the
first occurred at the very start of HD and lasted approximately one minute,
and the second peaked to a lesser extent at 20 to 26 minutes after the
initiation of HD. The extent of NO release was dependent on the type of
dialysis membrane used. Areas under curves for blood NO concentrations
(in jrmol x mm) were as follows: CU, 450.8 163.3; PS, 247.3 150.6*;
PAN, 200.4 91.0* (*P < 0.05 vs. CU). During the first hour of HD (N =
6) blood NO concentrations were significantly higher at the outlet of CU
dialyzer than those found at the inlet. The areas under their curves (in
imol x mm) were 169.1 1.9 and 107.5 1.6, respectively (P < 0.001).
Areas under curves for blood NO concentrations measured for five
minutes following a five-minute in vitro incubation of 5 ml heparinized
uremic blood samples (N 10) with dialysis membranes (50 cm2) were as
follows (in nmol X mm): CU, 2380 289*; PS, 1293 45*; PAN, 1117
37*; control, 502 56 (*P < 0.05 vs. control). The addition of sodium
heparin to uremic blood platelet suspension induced an immediate rise in
NO release in a dose-dependent manner, which proved to be a hyperbolic
relationship. During HD with CU (N = 6), PS (N = 6) and PAN (N = 6)
membranes blood plasma cGMP concentrations significantly increased,
particularly at 20 and 60 minutes of the procedure. No significant
differences in blood plasma cGMP levels were found between individual
dialysis membranes, and no significant correlations were observed be-
tween blood plasma cGMP levels and blood NO concentrations. The
results indicate that during HD NO is released in the peripheral blood due
to blood-membrane and heparin-blood platelet interactions. The extent of
intradialytic NO release is dependent on the type of dialysis membrane
used (CU > PS — PAN).
During hemodialysis (HD) blood contact with a foreign surface
initiates and promotes a variety of complex and interrelated
events, which lead to an acute inflammatory response. In partic-
ular, activation of peripheral blood phagocytes and coincident
blood platelet stimulation induce the release of many inflamma-
tory mediators into the extracellular environment, which have
been detailed by recent comprehensive reviews [1—3]. On the
other hand, it has been shown that monocytes [4], neutrophils [4,
5] and blood platelets [6] contain NADPH-dependent nitric oxide
synthases (NOS), which catalyze the conversion of L-arginine into
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L-citrulline and nitric oxide (NO) [4, 7, 8]. NO has been identified
as a potent and pleiotropic mediator of numerous physiological
and immunological reactions [4, 8]. Depending on its oxidation-
reduction status, NO, generated at high levels at sites of inflam-
mation [9_Il], may exert either protective or destructive effects
[12].
In view of HD-induced peripheral blood cell activation, en-
hanced NO generation should be expected to occur during HD.
Increased blood plasma levels of nitrites (NO2) and nitrates
(NO3—), the products of NO metabolism, after HD in patients
who had intradialytic hypotensive episodes [13] as well as indirect
evidence derived from intradialytic measurements of blood
plasma N02/NO3 levels [14] seem to support our supposition.
Therefore, we have undertaken these studies to evaluate the
extent of NO release in the peripheral blood during HD with
different membranes and to determine some of possible factors
responsible for this phenomenon. We applied continuous direct
monitoring of NO release with a highly specific NO-selective
electrode, which polarographically measures the concentration of
gaseous NO in aqueous solutions.
Methods
Patient population
The studies were performed on 10 chronic uremic patients (2
women, 8 men), aged 41 8 years. They had been on regular HD
treatment for I to 14 years (mean 6.6 3.4 years). No symptoms
of infection or aluminum toxicity were found in any patient. None
of them suffered from symptomatic hyperparathyroidism; their
blood serum calcium and phosphate concentrations were effec-
tively controlled by using calcium carbonate, elimination of high-
phosphate-containing food intake and adequate efficacy of HD.
The patients were not given nitrates, arachidonic acid cyclooxy-
genase inhibitors, calcium antagonists, angiotensin converting
enzyme inhibitors, antiplatelet drugs or other drugs known to
affect immune functions. They did not receive blood transfusions
within the last two months. Blood recirculation in their arterio-
venous fislulas did not exceed 7%. Before HD their mean arterial
blood pressure ranged from 108 8 mm Hg to 111 10 mm Hg,
and it did not significantly change during the procedures irrespec-
tive of the type of the dialysis membrane used.
The protocol of the studies was approved by the Regional
Commission for Ethics in Research.
Measurement of NO release during HD
Measurements of NO release in the peripheral blood were
performed during three consecutive four-hour HD procedures on
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an AK-IOU machine (Gambro, Lund, Sweden) using dialyzers with
different membranes: cuprophane (CU) (Clirans C-1O1; Terumo
Corp., Tokyo, Japan), polysulfone (PS) (F-5; Fresenius AG, Bad
Homburg, Germany) and polyacrylonitrile (PAN) (Biospal 2400S;
Hospal, Meyzieu, France). All dialyzers were single-used and
their surface areas were I m2. The blood flow rate was 200 ml/min,
and acetate dialysate flow rate was 500 mI/mm. Water for
dialysate preparation was purified by reverse osmosis using the
WRO-lO system (Gambro).
Before HD dialyzer and blood lines were filled with 0.9%
sodium chloride. Anticoagulation was performed with sodium
heparin given as an intravenous bolus of 5000 IU just before HD
followed by a continuous infusion at a rate of 1250 lU/hr.
Continuous monitoring of NO release in the peripheral blood
was performed by means of an Iso-NO meter (World Precision
Instruments; Sarasota, FL, USA) using a sterile NO sensor probe
[151 inserted vertically into the arterial blood line between arte-
riovenous fistula and the dialyzer; the tip of the electrode was
dipped 1 mm into the lumen of the arterial blood line. The
gaseous NO concentration range measured by this device was I
flM to 20 jxM. Prior to the experiments calibration of the electrode
was performed with potassium nitrite (Sigma Chemical Co., St.
Louis, MO, USA) as a generator of NO and calibration line was
prepared. Measurements of gaseous NO concentrations were
started at the moment, when the first portion of the blood came
into contact with the electrode surface after the blood pump had
been set in motion.
In 6 of 10 chronic uremic patients measurements of blood NO
concentrations were performed at the inlet and at the outlet of
CU dialyzer simultaneously by the location of NO sensor probes
in the arterial and venous blood lines, respectively (the second
Iso-NO meter became available courtesy of Prof. Dariusz Nowak,
Department of Pneumonology, Medical University, Lód, Po-
land). The measurements were limited to the first hour of HD
only, because the changes in blood NO levels were the most
conspicuous in that period. In these studies all HD procedures
were performed without convection (TMP = 0).
In vitro NO generation during incubation of blood samples with
dialysis membranes
Before HD 5 ml blood samples were taken from the arterio-
venous fistula to polystyrene tubes containing heparin (10 lU/mi)
and 50 cm2 of CU, PS or PAN dialysis membrane. The control
tube did not contain any dialysis membrane. The tubes were
placed on the mechanical agitator and rotated around their long
axis with angular acceleration of 0.3 x g for five minutes at room
temperature. Immediately after the termination of the tube
rotation the NO sensor probe was dipped into the blood sample
and continuous monitoring of NO release was carried out for five
minutes as described above.
Effect of heparin on NO release by uren'uc blood platelets
Blood samples were drawn from the arteriovenous fistula
before HD into polystyrene tubes containing acid citrate dextrose
(10:1, vol/vol) and were centrifuged for 20 minutes at 2000 x g.
After separation of platelet rich plasma (PRP) 0.2 M citric acid
solution was added to obtain pH 6,5. Next, apyrase 10 lU/mi was
added and PRP was centrifuged for 15 minutes at 1000 >< g. Then
platelets were washed twice with a buffer containing sodium
chloride 128 m, sodium carbonate 4.26 m, sodium citrate 4.77
m, citric acid 2.35 m, glucose 5.5 ms'i, apyrase 10 lU/mi, pH 6.5.
Finally, the purified cells were resuspended in the modified
Hepes-Tyrode's buffer, pH 7.4, to a concentration of lO cells/mI
[161.
After insertion of NO sensor probe into 1.5 ml samples of blood
platelet suspension basal maximal responses of NO release were
determined as described by Tsukahara, Gordienko and Goligor-
sky [151. Platelet suspensions were then treated with 5 IU, 50 IU,
100 IU, 250 IU, 500 IU, and 1000 IU of sodium heparin, which
gave the final heparin concentrations of 3.33 lU/mI, 33.3 lU/mi,
66.7 lU/mi, 166.6 lU/mi, 333.3 IU/ml, and 666.7 lU/mi, respec-
tively. Immediately after the heparin addition the increments of
maximal responses of NO release were measured [15].
Blood plasma cyclic 3',5'-guanosine monophosphate (cGMP)
levels
In 6 of 10 chronic uremic patients before HD, at 20, 60, and 240
minutes of HD with CU, PS and PAN membranes, blood plasma
cGMP concentrations were determined with radioimmunoassay
using the Cyclic GMP [3H1 assay system (Amersham International
plc, Amersham, UK) according to recommendations of the man-
ufacturer. Blood samples were taken from the arteriovenous
fistula before HD and from the arterial blood line during HD.
Statistical analysis
After calculations of arithmetic means (X) and sos, the Wil-
coxon signed rank test was used for comparisons of paired data,
and the Mann-Whitney U-test was used for unpaired data [171.
To assess total amounts of NO released during HD procedures.
areas under curves for blood NO concentrations were calculated
using linear and multinomial interpolation. Next, the areas were
integrated numerically within the limits of measurement duration.
As initial calculations disclosed that results of interpolations did
not differ between both methods, results of linear interpolations
were taken for further analysis.
The differences were recognized as statistically significant when
P < 0.05.
Results
NO release in the peripheral blood during HD
Continuous monitoring of blood NO concentrations during HI)
disclosed similar patterns of changes irrespective of the type of
dialysis membrane used (Fig. 1). In the initial period of HD two
peaks in the blood NO levels were observed. The first and the
highest one occurred immediately after the first portion of blood
had reached the NO sensor probe and it lasted approximately one
minute. it was followed by another peak of a lesser extent, which
was reached at 20 to 26 minutes of HD. Then, blood NO con-
centrations progressively declined until the end of the procedure.
However, during this time period, blood NO levels displayed
some quantitative differences that were related to the type of the
membrane used (CU > PS PAN; Fig. I). Indeed, calculations
of areas under curves for blood NO concentrations revealed (Fig.
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Fig. 1. Blood NO concentrations (X) in the
course of time during four-hour HD with
cuprophane (CU, —), polysulfone (PS, — —) and
polyacrylonitrile (PAN, . .... dialysis membranes
in chronic uremic patients (N = 10). Insert.
Areas under curves (X SD) for blood NO
concentrations during the same FID procedures.
'P < 0.05 in relation to CU.
Fig. 2. Blood NO concentrations (X) at the inlet
(IN, —) and at the outlet (0U7 ) of
cuprophanc dialyzers during the first hour of HD
in chronic uremic patients (N = 6). Insert.
Areas under curves (X so) for blood NO
concentrations during the same lID procedures.
'P 0.001 in relation to IN.
1, insert) that NO releases during HD with PS and PAN mem- likewise, area under curve of blood NO concentration was signif-
branes were nearly twice lower than that observed during HD with icantly higher at the outlet than that at the inlet (Fig. 2, insert).
CU membrane (P < 0.05). NO release during HD with PAN
membrane was slightly lower than that during HI) with PS NO release drering in vitro incubation of blood with dialysis
membrane, but the difference was insignificant (Fig. 1, insert). inc/n branes
During simultaneous measurements of blood NO concentra- After the termination of five-minute incubation of uremic blood
tions in the arterial and venous blood lines NO appeared at the samples with different membranes significant increases in blood
outlet of the dialyzer with a thirteen-second delay in relation to NO concentrations were observed (CU > PS PAN > control;
the inlet and patterns of blood NO changes were similar at both Fig. 3). Comparisons of areas under curves for blood NO levels
ports. However, blood NO concentrations at the exit port were confirmed the existence of relationship between blood NO release
distinctly higher than those found at the entry port (Fig. 2); and the type of dialysis membrane (Fig. 3, insert).
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Effect of heparin on NO release by uremic blood platelets
Basal maximal response of NO release by unstimulated uremic
blood platelets was 192.6 22.7 nM/liter of cell suspension. The
addition of heparin to blood platelet suspension immediately
enhanced maximal response of NO release by these cells in a
dose-dependent manner, which proved to he a hyperbolic rela-
tionship (r = 0.9787; P < 0.005; Fig. 4).
Blood plasma cGM1' concentrations
Although the results of blood plasma cGMP determinations
during HD with different membranes had a rather wide scatter,
significant rises in cGMP levels were observed in relation to their
predialytic levels, particularly at 20 and 60 minutes of the proce-
dure (Fig. 5). However, no significant differences in blood plasma
cGMP levels were found between individual dialysis membranes.
Fig. 3. Blood NO concentrations (X) during five-
minute measurements following in vitro
incubation of uremic blood samples (5 ml; N =
10) with cuprophane (CU, —), polysulfone (PS,
— —) and polyac,ylonitrile (PAN, . . . .) dialysis
membranes (50 cm2). C (.--) is the control blood
5 sample without dialysis membrane. Insert.Arcas under curves (X SI)) for blood NO
concentrations during the same in vitro
experiments. *P < 0.05 in relation to C.
Also no significant correlations were observed between blood
plasma cGMP levels and blood NO concentrations at the inves-
tigated time points of HD with different membranes.
Discussion
Our continuous measurements of blood NO concentrations
revealed a two-peak pattern of their changes. The first and the
highest peak, observed at the start of HD, lasted approximately
one minute. The other peak was reached at 20 to 26 minutes of
the HD procedure. The reasons for such a pattern of changes in
blood NO levels seem to be complex and unclear. To our
knowledge, intradialytic continuous measurements of blood gas--
eous NO concentrations have not yet been reported. By determi-
nations of N02/N03, measurable NO metabolites, Grosskopf
et a! [141 found a progressive decline in blood plasma concentra-
tions during HD, possibly due to its elimination prevailing over
production, and the intradialytic NO generation rate was higher
than interdialytic one. On the other hand, Yokokawa et al [13],
who measured blood plasma NO2/NO3 concentrations before
and after HD only, found a rise in their postdialytic blood plasma
levels in patients with hypotensive episodes during HD, while they
remained unaltered in patients whose mean blood arterial pres-
sure did not change.
Our present studies do not permit an unequivocal determina-
tion of the mechanisms of these changes. 1-lowever, at least sev-
eral factors seem to he contributors. First, due to increased
blood turbulence within the arteriovenous fistula, lIstula needles,
blood lines and dialyzers during HD, cndothelial cells as well as
blood cells are exposed to enhanced shear stress [18, 19], which
is known to augment NO release from the endothelial cells, blood
platelets and neutrophils [4, 101. A sudden increase in blood
turbulence is observed particularly at the moment when the
blood pump is set in motion, which can explain to some extent
the origin of the first peak in blood NO level. We also cannot
exclude that the first blood NO concentration peak may be related
to the administration of a loading dose of heparin just before the
start of HD. Heparin was found to promote NO production by
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Fig. 4. Relationship between maximal responses of NO release by uremic
blood platelets (N = 10) in vitro and heparin concentration. NO concentra-
tions represent their increments (X SD) in relation to the basal maximal
response of NO release by unstimulated cells expressed as 0. y = 579.8x
÷ (181.8 + x); r = 0.9787; P < 0.005.
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*human vascular endothelial cells in culture [20]. Next, as heparin
activates blood platelets [21] by causing aggregation and release of
granule contents, and aggregating platelets are known to release
NO [22], this led us to suppose that heparin effects on blood
platelets may be an additional factor responsible for NO release
during HD. Indeed, in our in vitro experiments heparin signifi-
cantly increased the NO release from uremic blood platelets in a
dose-dependent manner, which proved to be a hyperbolic rela-
tionship.
In our studies the second peak of blood NO concentration was
reached at 20 to 26 minutes of I-ID. Due to its time coincidence
with the most intensified blood platelet [2] and phagocyte [3]
activation and increased formation of platelet-neutrophil and
platelet-monocyte aggregates across the dialyzer [23], it seems
that this rise in the gaseous NO generation can be attributed, at
least partially, to the NOS stimulation accompanying the activa-
tion of these cells.
Continuous monitoring of blood NO levels and calculations of
areas under curves for these concentrations disclosed that during
four-hour HD the largest NO production was observed with the
CU membrane, while it was nearly twice lower with PS and PAN
membranes. Moreover, blood NO levels at the outlet of the CU
dialyzer were significantly higher than those found at the inlet.
Therefore, the results suggest that the extent of intradialytic NO
generation is also dependent on the direct blood-membrane
interaction and on the dialysis membrane hemocompatibility.
Further support For this suggestion was provided by our in vitro
experiments, in which the addition of different dialysis membranes
to uremic blood samples was found to significantly enhance NO
generation, and the differences in its extent were similar to those
observed in vivo (CU> PS - PAN). This seems to correspond to
the reported more significant expression of NOS mRNA and
greater NOS activity in cultured murinc endothelial cells follow-
ing their coincuhation with donor blood samples taken during
blood recirculation in CU dialyzer in comparison with those taken
during recirculation in polymethylmetacrylate dialyzer [24].
Progressive intradialytic declines in blood NO concentrations
that occur in the later hours of HD might result from a feedback
inhibition of NOS activity by NO [25]. It might also be related to
down-regulation of phagocyte function [3], which develops follow-
ing their acute stimulation in the initial period of HD. The
contribution of HD-induced elimination of some blood plasma
components to the decline of blood NO levels is difficult to assess.
Both NOS inhibitors [26, 27] and NOS activators [26, 28] have
been identified in the uremic blood plasma. Hence, under these
circumstances NO production will be determined by the balance
between NOS inhibitors and activators.
The released NO binds to and activates guanylate cyclase, both
the soluble and membrane-bound form [4, 291, with a subsequent
increase in cGMP levels. Therefore, intradialytic changes in blood
NO concentrations should be accompanied by alterations in blood
plasma cGMP levels. In addition to NO, plasma cGMP levels are
also affected by atrial natriuretic peptide (ANP) secretion and are
directly proportional to fluid overload in HD patients [30, 31].
However, if blood plasma cUMP levels were exclusively depen-
dent on fluid elimination with a subsequent decrease in ANP
secretion, then a progressive decrease in plasma cGMP levels
would occur. Meanwhile, in our studies significant rises in blood
plasma cGMP concentrations were observed during HD, partic-
ularly at 20 and 60 minutes of the I-ID session. This seems to l)c
another indirect evidence of an enhanced NO release in the
peripheral blood during HD. However, no significant differences
in blood plasma cGMP levels were found between individual
dialysis membranes and no significant correlations were observed
between blood plasma cGMP levels and blood NO concentrations
at the time points of HD with different nicrnhranes that were
investigated, which might he related to the rather small nwnher of
patients in this study.
The clinical significance of NO release in the peripheral blood
during 1-ID in chronic uremic patients may be multifarious. As
membrane-dependent differences have been disclosed in NO
release in the peripheral blood, determinations of blood NO
levels may he useful for the assessment of dialysis membrane
hemocompatibility.
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Fig. 5. Bloodplasma cGMP concentrations
(X so) during HD with cuprophane (CU),
polysulfone (PS) and polyac,ylonitrile (PAN)
membranes in chronic uremic patients (N = 6).
< 0.05 in relation to 1) minutes.
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Next, as NO serves as a paracrine or autocrine factor in
vasodilation [4, 10], it has been hypothesized [32] that HD-
associated hypotension is mediated by the production of NO in
vascular smooth muscle cells. In the studies of Yokokawa et al
[13] postdialytic blood plasma N02/N03 concentrations were
significantly increased in patients with HD-associated hypotensive
episodes, and, like plasma cGMP levels, they significantly corre-
lated with mean arterial blood pressure. In our patients no
hypotensive episodes were observed during the investigations.
Perhaps increased NO production did not unsettle the balance
between vasoconstricting and vasorelaxing factors, and thereby
peripheral vascular resistance remained unaffected. Alternatively,
the increased blood NO levels released towards the abluminal
side of the blood vessel wall might not reflect its local concentra-
tions at the level of vascular smooth muscles, which affect systemic
vascular tone [4].
As during HD enhanced generation of reactive oxygen com-
pounds takes place [331, the effects of NO release on intradialytic
oxidative stress remain to be determined. On the one hand, NO
was shown to inhibit neutrophilic production of reactive oxygen
compounds by interacting with NADPH-oxidase [34] and xan-
thine oxidase [351. On the other hand, NO can combine with
superoxide anion to form peroxynitrite, a potent oxidant that can
cause tissue damage [36]. Moreover, NO can induce dose-depen-
dent breaks in DNA in vitro by nitrosation of amines on guanine
and adenine [371, and therefore its contribution to increased risk
of malignancy in uremic patients on regular hemodialysis treat-
ment [38] cannot be excluded. Finally, as NO leads to nitrosyla-
tion of metal- and thiol-containing proteins [8], possible biological
sequelae of these processes in chronically hemodialyzed patients
need to he established.
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